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Abstract
Animal models are frequently used for in vitro physiologic and drug transport studies of the colon, 
but there exists significant pressure to improve assay throughput as well as achieve tighter control 
of experimental variables than can be achieved with animals. Thus development of a primary in 
vitro colonic epithelium cultured as a high-resistance with transport protein expression and 
functional behavior similar to that of native colonic would be of enormous value for 
pharmaceutical research. A collagen scaffold in which the degree of collagen cross-linking was 
present as a gradient was developed to support the proliferation of primary colonic cells. The 
gradient of cross-linking created a gradient in stiffness across the scaffold enabling the scaffold to 
resist deformation by cells. mRNA expression and quantitative proteomic mass spectrometry of 
cells growing on these surfaces as a monolayer suggested that the transporters present were similar 
to those in vivo. Confluent monolayers acted as a barrier to small molecules so that drug transport 
studies were readily performed. Transport function was evaluated using atenolol (a substrate for 
passive paracellular transport), propranolol (a substrate for passive transcellular transport), 
rhodamine 123 (Rh123, a substrate for P-glycoprotein) and riboflavin (a substrate for solute carrier 
transporters). Atenolol was poorly transported with an apparent permeability (Papp) of < 5×10−7 
cm s−1 while, propranolol demonstrated a Papp of 9.69×10−6 cm s-1. Rh123 was transported in a 
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luminal direction (Papp, efflux/Papp, influx =7) and was blocked by verapamil, a known inhibitor of P-
glycoprotein. Riboflavin was transported in a basal direction and saturation of the transporter was 
observed at high riboflavin concentrations as occurs in vivo. It is anticipated that this platform of 
primary colonic epithelium will find utility in drug development and physiological studies since 
the tissue possesses high integrity and active transporters and metabolism similar to that in vivo.
1. Introduction
Two fundamental determinants of drug absorption and excretion in the intestine are 
epithelial permeability and molecular transport. Handling of drugs in the colon differs 
significantly from that in the small intestine with the colon possessing greater barrier 
function, a distinct repertoire of transporters, and a lower surface area.1 In the colon, 
lipophilic xenobiotics readily diffuse across the colonic epithelium, but hydrophilic 
compounds must be transported.2 Transport proteins are located on the luminal-facing and 
basal membranes of enterocytes where they transport compounds toward the bloodstream or 
efflux back into the colonic lumen.3 Two major classes of transporters are present in the 
colon, ATP-binding cassette (ABC) transporters and the solute carrier transporters (SLC). Of 
the ABC transporter family, p-glycoprotein (P-gp), multidrug resistance-associated protein 2 
(MRP2) and breast cancer resistance protein (BCRP) mediate ATP-dependent efflux and 
play key roles in reducing drug bioavailability and increasing drug resistance of tumor cells.
2,4 SLC transporters, such as organic cation and anion transporters (OCT and OAT), and 
peptide transporter 1 (PEPT 1), require an ionic, electrochemical, or concentration gradient 
for transport and participate in the movement of a variety of substrates including peptides, 
sugars, and inorganic and organic ions.4–6 SLC transporters are important for absorption of 
charged molecules, particularly cationic pharmaceuticals such as metformin and oxaliplatin.
7 The study of epithelial permeability and transport using primary colonic intestinal 
epithelium in an in vitro system would be valuable for understanding the molecular 
mechanisms of these transport proteins in the colon.
Traditionally, in vitro studies using primary colonic cells have required tissue explants, but 
these are short lived and challenging to manipulate.8 Cell lines derived from colon 
carcinomas have also been used as these can be maintained for prolonged periods in culture, 
but suffer from genetic mutations and genome instability.9,10 Advances in stem-cell culture 
techniques have enabled primary intestinal epithelial cells from a variety of mammalian 
species to be cultured and propagated buried within Matrigel as spheroidal structures known 
as organoids.11 Organoid culture supports proliferation and differentiation of stem cells to 
generate all of the cell lineages present in the colonic epithelium.11 Organoid-based 
transport assays have been devised to assess P-gp and cystic fibrosis transmembrane 
conductance regulator (CFTR) function.12,13 However, organoids are enclosed structures 
making it a challenge to access the lumen and the apical surfaces for absorption or transport 
studies. Additionally, large numbers of transporters are located on the enterocyte apical 
brush border which is not accessible in an organoid and the addition of drugs to the 
outwardly facing basal face of the epithelium can lead to inaccurate transport assessment. 
Development of a monolayer culture of primary cells free of these restrictions would be 
advantageous.
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Primary cells obtained from freshly isolated colonic crypts or from colonic organoids have 
been grown as monolayers on membranes with thin coatings of extracellular matrix (ECM).
14 However, transporter expression and function in these primary cultures have not been well 
characterized. In addition, the lack of an ECM layer with an appropriate stiffness may cause 
abnormal adhesion, proliferation and differentiation of the cultured cells. Recently, our 
group developed a self-renewing monolayer culture of primary colonic epithelium on 
collagen that enabled stem and progenitor cells to adhere, proliferate and differentiate into 
all of the expected cell lineages.15 However, obtaining a contiguous monolayer with high 
transepithelial electrical resistance (TEER) as needed for transport studies was challenging 
since forces exerted by the cells detached the collagen scaffold from the underlying porous 
membrane. Here we describe a primary colonic epithelial monolayer formed on the planar 
surface of an ECM scaffold with the appropriate stiffness to support a proliferative colonic 
epithelial monolayer yet sufficiently rigid to resist cell-based deformation. The monolayers 
were characterized with regards to parameters critical for drug transport assays, including 
TEER, permeability, and gene and protein expression by mRNA expression and mass 
spectrometry, respectively. Functional assays for representative members of the ABC and 
SLC transporter families were then validated and examined in the monolayers.
2. Experimental Section
Preparation of collagen scaffolds.
Non-cross-linked collagen scaffold was prepared as described previously by gelling collagen 
(1 mg/mL, 2.2 mm thick) in the wells of a standard 6-well plate (effective growth area of 
membrane 4.2 cm2).15 Collagen scaffolds with a gradient of cross-linking was prepared by 
adding collagen (200 µL at 1 mg/mL) to individual Transwell inserts (BD Falcon #353180, 
transparent PET membrane, 1.6×106 pores/cm2, effective cell culture area of 0.9 cm2). Then 
1 mL of PBS was added to upper and lower reservoirs of each Transwell, and the plate was 
placed at 4°C for 30 min. The PBS in the lower reservoir was then replaced with the cross-
linking reagents 1-ethyl-3-(3- dimethylaminopropyl)-carbodiimide (EDC, 353 mM) and N-
hydroxysuccinimide (NHS, 88 mM) in 2-(N- morpholino)ethanesulfonic acid (MES, 4°C, 
1.5 mL). PBS (4°C, 0.5 mL) was added to the upper reservoir. The multi-well plate was 
maintained at 4°C for 40 min after which time the reservoir fluid was replaced with PBS to 
remove cross-linking reagents (Supporting Information). The scaffold was immersed in 
deionized water to leach out EDC and NHS and sterilized with 70% ethanol for 5 min, 
washed with PBS, and were then stored in PBS for a minimum of one week before usage to 
insure removal of residual cross-linking reagents.
Monolayer culture of colonic epithelial cells.
Colonic epithelial cells were isolated from the crypts of mice expressing cytomegalovirus 
enhancer plus chicken actin promoter (CAG)-DsRed or wild- type (WT) mice as described 
previously.15,16 Propagation of monolayers possessing colonic stem cells was previously 
described and is briefly summarized in the Supporting Information.15 To generate 
contiguous monolayers, cells from a monolayer culture were suspended in EM and plated on 
gradient cross-linked scaffolds (900,000 cells/cm2). Dead cells on the surface of the 
monolayers were removed each day starting at day 2 by gently pipetting the medium up and 
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down ×5 using a 1 mL pipette followed by replacement of the media. The monolayer visibly 
covered the entire surface of the scaffold by 3–5 days. To compare cell growth on the 
gradient cross-linked scaffolds to the non cross-linked collagen scaffolds, cells (900,000 
cells/cm2) were added to 12-well Transwell plates containing gradient cross-linked scaffolds 
and 24-well Transwell plates with neutral collagen scaffolds. By day 2, monolayers of cells 
were visible on both scaffolds. Cells were then fixed using 4% paraformaldehyde and 
stained using Hoechst 33342 to calculate coverage.
Measurement of TEER.
The resistance between the upper (luminal, U) and lower (basal, B) surfaces of confluent 
monolayers cultured on gradient cross-linked scaffolds was measured using an EVOM2 
epithelial Volt/Ohm meter (World Precision Instruments, Sarasota, FL). The resistance was 
measured with EM in the upper and lower reservoirs on each side of the scaffold (n = 3). 
The resistance with a monolayer of cells was corrected by subtracting the average resistance 
of scaffolds without cells and normalized by multiplying the effective scaffold surface area 
(0.9 cm2) to provide a TEER in units of Ω cm2.
Measurement of the permeability of confluent cell monolayers.
The permeability of the confluent monolayers to LY, a water-soluble, small molecular 
weight dye (M.W. 442.2 g/mol) was assessed since this molecule is not actively transported 
by the colonic epithelium. LY (500 μM, 0.5 mL) in EM was added to the upper reservoir of a 
confluent monolayer on a collagen scaffold in a Transwell insert. The lower reservoir was 
filled with EM (1.5 mL). Fluid was sampled (80 µL) from the lower reservoir over 6 h. An 
identical amount of EM was added back to the lower reservoir after each sampling. The 
amount of LY in the lower reservoir was quantified by fluorescence (Spectramax M5, 
Molecular Devices, ex: 428 nm, em: 520 nm). The apparent permeability (Papp) of LY 
diffusion was calculated at 6 h after addition of the analyte to one of the reservoirs since Papp 
of LY remained within 10% of this value 3 h after initiating the experiment:17 Papp was 
calculated as follows: Papp= (dQ/dt) (1/A C0)(cm s−1)
Where dQ/dt is the steady state flux towards the lower reservoir, C0 is the initial 
concentration in the upper reservoir and A is the scaffold’s surface area (0.9 cm2).
mRNA expression analysis.
Cells grown as confluent monolayers were collected at days 3 (526±56 Ω cm2), 4 (623±15 Ω 
cm2) and 5 (407±53 Ω cm2). Each sample consisted of the cells from a single insert of a 12-
well Transwell. Independent replicates (3) were performed for each data point. Isolated 
crypts from the same mouse from which the monolayers were established were used for 
comparisons. Total RNA was isolated using MicroRNAqueous Kit (Ambion). RNA quality 
was assessed by bioanalyzer, and all samples demonstrated an RNA Integrity Number (RIN) 
greater than 8.0. Illumina sequencing libraries were generated from this RNA using 
SMARTer® Stranded Total RNA Sample Prep Kit with Illumina indexes using manufacture 
protocols. The quality of libraries was evaluated by bioanalzyer, all libraries passed quality 
control, and were pooled according to manufacturer specifications for sequencing on an 
Illumina NextSeq 500 instrument with a single end 75 bp high output kit. Data was 
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processed through computational piplines described in the GEO entry. Each sample was 
sequenced to a depth between ~2 × 106 to ~6 × 106 reads/sample (ave= 4.1 × 106 +/− 1.4 × 
106 ). The number of genes detected per sample ranged from 12,000 to 14,500 genes/sample 
(ave= 14,001 +/− 687).
To evaluate the transporter expression, global level mRNA expression of both SLC and ABC 
transporters at 1% false discovery rate (FDR) over time was performed. FDR accounts for 
false expression within the significant genes and therefore provides a more accurate 
statistical result.18 Here we set the FDR to 1% such that the false positive rate is ≤1 gene out 
of 100.
Measurement of transporter protein expression by mass spectrometry.
Quantitative targeted absolute proteomic conducted by selected reaction monitoring mass 
spectrometry (QTAP SRM) was used to determine whether selected transporter proteins 
were detectable within the cell monolayers and fresh crypts. A stable isotope-labeled 
reference proteotypic peptide (standard, Table S2) at a known concentration was added to 
the membrane fraction sample prior to LC-MS/MS analysis.19 Absolute quantification was 
based on the ratio between the SRM signals (Table S2) of the analyte and that of the 
standard peptide. Using the known concentration of the standard added to the sample, the 
absolute concentration of the analyte was directly calculated through a linear correlation. 
Samples for analysis by QTAP SRM were prepared from 12 monolayers grown on 12-well 
Transwell inserts pooled and homogenized in hypotonic buffer (1 M tris HCl, 1 M NaCl, 
0.15 M MgCl2). The samples were centrifuged (10,000 rcf at 4°C), supernatant was taken 
off and the protein was pelleted by ultracentrifugation (55,000 rcf at 4°C). The resulting 
protein pellet representing the membrane fraction was re-suspended in fresh PBS and 
analyzed. The average TEER of samples was 180±20 Ω cm2 (day 2), 1140±140 Ω cm2 (day 
4), and 320±20 Ω cm2 (day 6). The TEER dropped on day 6 as differentiated cells began to 
reach the end of their life span and die.
Measurement of transport across the monolayers.
For all transport studies, monolayers grown for 4–5 days with TEER >300 Ω cm2 were used. 
A mix of atenolol (ATL, 10 µM) and propranolol (PPL, 10 µM) was added to the upper 
reservoir (apical face of the monolayer). To assess transport, fluid from the lower reservoir 
was collected at 3 h. The concentration of ATL and PPL in the lower reservoir were 
determined using HPLC-triple quadrupole mass spectrometry (MS/MS, PESciex API 3000, 
AB Sciex, equipped with Shimadzu LC System) with multiple reaction monitoring (MRM).
20 A C- 18 analytical column with linear gradient from 100% water with 1% formic acid to 
80% acetonitrile with 1% formic acid over 8 min (0.3 mL/min) was used for the separation. 
Metoprolol was used as an internal standard. Eluted species were subjected to electrospray 
ionization (positive mode) and transitions of 267.2/190 (m/z of precursor ion/product ion) 
for atenolol, 260.2/116.1 for propranolol, and 268.2/116.1 for metoprolol were monitored.
To measure the activity of the p-gy transporter, Rh123 (10 µM) in EM medium was added to 
the lower (1.5 mL) or upper (0.5 mL) reservoir. The opposing reservoir was filled with EM 
(0.5 mL, upper or 1.5 mL, lower). After 2 h, 80 µL of media was collected from the 
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appropriate receiving reservoir and Rh123 accumulation was determined by measuring 
Rh123 fluorescence (excitation: 490 nm, emission: 529 nm). The efflux over influx ratio was 
calculated considering the Rh123 diffusion in respective blank scaffolds. In experiments to 
confirm that p-gy was the transporter responsible for Rh123 transport, the p-gy inhibiter 
verapamil (200 µM) was incubated with the monolayer for 1 h prior to addition of Rh123. 
Then Rh123 (10 µM) with verapamil (200 µM) in EM was added to the lower reservoir and 
fluid was collected from the upper reservoir followed by quantification of the Rh123 
concentration in the medium. The duration of the inhibition assay was 2 h similar to that of 
the Rh123 transport assay.
To measure the activity of the SLC52A3 transporter, riboflavin (1 or 5 µM in EM) was 
added to the upper reservoir and the fluid in the lower reservoir was sampled at 3 and 24 h. 
Riboflavin was measured using high performance liquid chromatography (HPLC, Agilent 
1100 Series) with fluorescence detection (ex: 368 nm, em: 515 nm) and quantified against a 
calibration curve (250 nM to 2 µM). A C-18 analytical column was employed with a 
gradient of 100% water to 100% acetonitrile over 10 min (0.5 mL/min).
Statistics.
Gene expression profiles estimated from mRNA-seq were compared across the 2-, 3-, and 5-
day time points, then contrasted against the crypt samples. Initial evaluation of these profiles 
was performed using principal component analysis and hierarchical clustering to assess 
quality and overall experimental signal. The hypothesis regarding differential expression 
across time was tested with DESeq221 with time points encoded as three categories to test 
the null hypothesis that the mean expression is the same across these conditions. Parametric 
p-values from DESeq2 were adjusted for multiple comparison using the method of 
Benjamini and Hochberg (1995).22 The resulting adjusted p- values (Padj) for individual 
comparisons were represented using symbols in the figures. For the remaining statistical 
comparisons, one-way ANOVA with Tukey’s comparisons were used for multiple samples. 
For comparison of two groups, a two-tailed t-test was used. These statistical tests were 
performed at a significance level of 0.05 using GraphPad Prism (GraphPad Software, Inc. La 
Jolla, CA). The Padj/P were represented as follows in the figures: * for P/Padj <0.05, ** or Ɨ 
for P/Padj <0.01, *** or ‖ for P/Padj <0.001, **** or ¥ for P/Padj <0.0001. Unless stated 
otherwise, the average and standard deviation (SD) of the data points were used to display 
the data (average ± SD).
3. Results and Discussion
Generation of collagen scaffolds with a stiffness gradient.
We previously demonstrated that colonic epithelial cells could be cultured on a collagen 
scaffold to create a self-renewing monolayer of primary intestinal cells.15 However, when 
these cells were cultured on a collagen scaffold overlaid on a porous membrane instead of a 
solid polystyrene surface, the scaffolds contracted over time most likely due to contractile 
forces generated by the cells (Figure 1A) (n=3 scaffolds). A scaffold with an upper surface 
sufficiently soft to enable robust cell attachment and proliferation, yet with adequate rigidity 
to resist cellular forces would be optimal for culture of the colonic epithelial cells. Small 
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molecules such as EDC and NHS are expected to require on average several hours to diffuse 
through the 2.2-mm-thick collagen scaffold.23 Thus, selective addition of these cross-linking 
reagents to the lower surface of the collagen scaffold might yield a region of sufficient 
stiffness at its base to resist deformation, yet leave the upper surface with properties suitable 
to support cell attachment and proliferation. To test this possibility, EDC and NHS were 
added to the lower reservoir of a Transwell containing a non-cross- linked collagen scaffold 
while buffer alone was added to the upper reservoir (Figure 1C). The upper surface of the 
scaffolds cross-linked with the reagents in the lower reservoir demonstrated a stiffness of 
395 ± 370 Pa in which 18% of measurements were <100 Pa. While the overall average was 
higher than that of non-cross-linked collagen (21 ± 12 Pa, n=5 scaffolds), the stiffness was 
significantly less than that of the scaffold surface in direct contact with the cross-linking 
reagents (see below). The pore size of the collagen on the upper surface (350 ± 120 nm) and 
of neutral collagen (390 ± 240 nm) was also similar (Figure 1D,E). When the cross-linking 
reagents were added to the upper reservoir, the stiffness of the upper surface of the collagen 
exposed directly to EDC/NHS was significantly greater still (2391 ± 2215 Pa, p<0.0001, n=5 
scaffolds). These data suggested that a gradient of cross-linking or stiffness might exist 
through the scaffold with the greatest degree of cross-linking in the collagen nearest the 
reservoir containing EDC/NHS. Forming a gradient in a similar manner using a readily 
visualized Alexa Fluor™ 594 NHS suggested that such a gradient was feasible (Figure S1). 
When primary colonic epithelial cells were cultured on the upper surface of collagen cross-
linked from the lower reservoir, the cells attached and proliferated and did not deform the 
collagen (Figure 1B, Figure S2).
Characterization of primary colonic epithelial cell growth on the gradient cross-linked 
scaffold.
Although the cells attached to the gradient cross-linked scaffold, it was important to 
understand whether the primary cells were comparable to that previously described for 
growth on non-cross-linked collagen.15 The rate of cell growth on the gradient cross-linked 
scaffold (cross-linked from the lower reservoir) was compared to that on non-cross-linked 
collagen by measuring the percentage of scaffold surface area coverage over time. At day 2, 
the cells on the gradient cross-linked scaffold grew more slowly than those on the non-cross-
linked scaffold (Figure 1F). By day 5, however, the cells on the gradient cross-linked 
scaffold spanned the entire scaffold surface (0.9 cm2) with the cells evenly distributed and 
tightly packed (Figure 2A, Figure S2). A cross-section through the cells and scaffold 
demonstrated a single layer of cells with an average inter-nuclear distance of 9.7 ± 1.8 µm (n 
= 18 cells) similar to that previously reported in vivo (8.0 ± 2.3 µm).24 The monolayer of 
cells also exhibited an appropriate basal to luminal polarization (Figure 2B). Actin, known 
to be enriched in the brush border, was concentrated at the luminal surface where the 
microvilli reside in contact with the overlying aqueous medium.25 Integrin β4, a ligand for 
laminin in the ECM, was located along the basal aspect of the cells adjacent to the scaffold.
15 The tight junction proteins (E-cadherin, zonula occludens-1 (ZO-1) were at high density 
at the cell-cell borders as in vivo (Figure 2C, D).15,25
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Identification of cell types present within the monolayer.
mRNA expression analysis suggested that the cells of the monolayer became increasingly 
differentiated as they reached confluency (Figure S3,4). However, it was important to 
confirm that the synthesis of proteins characteristic of differentiated cells (Muc2 in goblet 
cells and ALP in enterocytes) also increased over time since it is the differentiated cells that 
participate in transport of molecules. Absorptive enterocytes that are responsible for 
transport across the colonic epithelium produce ALP and were readily identified at day 3 of 
culture.26 By day 5, the monolayer exhibited significantly increased ALP compared to day 4 
and significantly decreased EdU incorporation compared to day 2 suggesting that the 
monolayers were increasingly comprised of differentiated cells (Figure 2E, Figure S3,4).
Measurement of cellular junction gene expression in the monolayers.
Colonic epithelial cells form a high resistance barrier enabling the cells transport molecules 
even against a concentration gradient.27 Tight junctions are the gatekeepers for diffusing 
molecules while adherens junctions are associated with initiation of contacts between cells.
28 For all monolayer culture times, mRNA expression of most genes encoding for tight and 
adherens junction proteins was at comparable or greater levels relative to that found in fresh 
crypts (Figure 3A).27,29 The expression of these critical genes for colonic barrier function in 
the epithelium suggested that the monolayers might have cell-cell borders of sufficient 
integrity to act as a barrier to ions and other small molecules.
Measurement of monolayer TEER and permeability.
The ability of the confluent monolayer grown on the gradient cross-linked scaffold to act as 
a barrier to the movement of ions and larger molecules was assessed by measuring both the 
TEER and the perm0ability of lucifer yellow (LY). TEER was measured over time as the 
monolayers grew to confluency. On day 2 when the cells were present largely in isolated 
patches, the TEER was not significantly different from that of the scaffold without cells 
(170±10 Ω cm2 vs. 160±10 Ω cm2, n = 5 replicates from 1 male mouse, p=0.128). By days 
3–5, many of the cell patches had expanded and merged and the TEER increased 
significantly to 240±140 Ω cm2, 440±80 Ω cm2, and 390±60 Ω cm2 for days 3–5, 
respectively (Figure S6A). To evaluate the reproducibility of high-TEER monolayer 
generation, 18 monolayers were grown on cross-linked scaffolds. Seventeen (94%) produced 
monolayers with TEER >290 Ω cm2. However, the average TEER values were >390 Ω cm2 
for all animals demonstrating formation of monolayers with excellent barrier integrity 
(Figure S6B). The most commonly used intestinal cell type used for barrier/permeability 
studies is Caco-2, a human colonic adenocarcinoma cell line that typically achieves a TEER 
of 420 to 660 Ω cm2 when grown to confluency and differentiated over a 3-week period to 
an enterocyte-like cell.30 Overall, the TEER value for the mouse monolayers suggested that 
these tissues would be of sufficient integrity for small-molecule transport studies.
Permeation of a small fluorescent non-transported molecule such as LY was used to further 
evaluate the integrity of the monolayers. LY is not a substrate for intestinal transporters.17,30 
The apparent permeability (Papp) of LY through the cell monolayer (days 4–5 of culture) 
was measured over time and compared to that of the scaffold alone (Figure 3C). Average 
Papp of LY reached a steady state flux of 2.44±1.64 × 10−7 cm s−1 for monolayers with a 
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TEER > 300 Ω cm2 (n=6) at 3 h after placement of LY into the upper reservoir. While Papp 
for LY is a more accurate indicator than TEER of monolayer permeability to small, 
nontransported molecules, Papp is more challenging to measure than TEER especially when 
handling the fragile monolayers of primary-cells. For this reason, we sought to correlate the 
TEER with Papp for LY so that the TEER could be used as a surrogate measure when 
assessing the suitability of monolayers in drug transport assays. Papp for LY was measured 
for monolayers at varying TEER values (Figure 3D). All monolayers with a TEER >300 Ω 
cm2 demonstrated a Papp <4.5×10−7 cm s−1 (n=6) for LY. A Papp >1×10–6 cm s-1 is 
typically characterized as “leaky” and not suitable for transport assays.17 Thus, based on the 
measured TEER and Papp values, the confluent monolayers comprised of primary, murine 
colonic epithelium possessed sufficient integrity for assay of molecular transport.
mRNA expression of transporters in the confluent monolayers.
The colon is known to have an active transport system in addition to that required for the 
reabsorption of water via osmosis following salt transport. mRNA expression analysis was 
performed for the confluent monolayers to identify which transporters might be present in 
these primary cell cultures. Transporter gene expression of both SLC and ABC transporters 
between day 5 and crypts vs. day 3 and crypts was compared. For ABC transporters, 8 
transporters in monolayers cultured for 5 days were changed at 1% FDR. Seven of eight 
demonstrated concordant increase with day 5 monolayers and crypts vs. day 3 monolayers 
(Figure S7A). Within SLC transporters, 59 transporters in monolayers cultured for 5 days 
were changed at 1% FDR. Of these SLC transporters, 51 of 59 demonstrated concordant 
increase when comparing day 5 monolayers and crypts vs. day 3 monolayers (Figure S7B). 
Overall, 59 SLC and ABC transporters are concordantly increased and 9 were concordantly 
decreased when comparing day 5 and crypts vs. day 3. As the culture time for the monolayer 
increased, the cells more closely resembled in vivo tissue with respect to the transporters 
examined.
Protein expression of transporters in the confluent monolayers.
The 5-day confluent monolayers were examined for the protein expression of a subset of the 
clinically relevant transporters identified by RNA expression (Table 1). P-gp, BCRP, MRP1, 
MRP3 transporters and the NaK ATPase ion channel peptides were identified by mass 
spectrometry (Figure S8, Table S1). The identified proteins exemplified a range of different 
transporter types and transport mechanisms. P-gp and BCRP are efflux secretory 
transporters present on the apical membrane of the cell and transport molecules from the 
cytosol into the colonic lumen.4 MRP1 and MRP3 are efflux absorptive transporters that are 
located on the basal membrane of the cells moving molecules from the interstitial (or basal) 
space into the cytosol.4 P-gp, MRP1/3 and BCRP all belong to the family of ATP-binding 
cassette (ABC) transporters and are energy dependent.2 These transporters play an important 
role in drug absorption and many drugs are transported by more than one of these proteins. 
For example, digoxin, paclitaxel and dexamethasone are substrates for P-gp; doxorubicin, 
topotecan and methotrexate are BCRP substrates; pravastatin and irinotecan are MRP1 
substrates; vincristine, etoposide and methotrexate are substrates for MRP3.31
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The levels of the transporters were also examined in crypts freshly isolated from mice for 
comparison to that in the monolayers. On day 2 of monolayer culture, the transporter 
proteins possessed an abundance well below that of the fresh crypts. However, as the 
monolayers matured and transitioned to the enterocyte lineage (days 4 and 6), most of the 
transporter levels approached that found in the crypts (Table 1, Figure S8). Overall, protein 
production of these transporters was consistent with the measured mRNA expression as well 
as the protein production and mRNA expression of fresh crypts. These data suggested that 
amount of the transporters in the confluent monolayers were representative of that found in 
vivo. Taken together, these transporter protein expression data demonstrated that multiple 
clinically important transporters were present in the monolayer and suggested that these 
colonic tissues might be suitable for functional transport assays.
Measurements of para- and transcellular transport.
ATL and PPL are beta-blockers used to treat hypertension and are also commonly used as 
substrates for para- and transcellular transport (ATL-paracellular, PPL-transcellular).32,33 
The high Papp of PPL measured for the day-5 monolayers suggested transcellular transport 
for this drug as highly permeable compounds exhibit Papp>2×10−6 cm s−1 (Figure 4A).17 
The Papp of ATL indicated a low permeability similar to that of LY (Figure 4A). The 
reported permeability of ATL and PPL for Caco-2 cells are 0.2–1(×10−6) cm s−1 and 4–25 
(×10−6) cm s−1 respectively; therefore, Papp values measured in our colonic monolayers are 
within the range of reported permeability values of Caco-2 cells.32,34,35 While the Papp of 
PPL for the colonic monolayers and Caco-2 was similiar to that estimated for in vivo tissue, 
the Papp of ATL for neither the colonic monolayers nor the Caco-2 cells was similar to that 
estimated for in vivo colon (Supporting Information).32–35 The source of this difference is 
unclear and may be due to differences in the intercellular connections between the systems 
or challenges in measuring in vivo permeabilities. Never-the-less these data do support the 
presence of a tight barrier in these murine colonic monolayers and selective absorption of 
compounds through the transcellular route.
Measurement of P-gp-mediated transport in the monolayers.
To determine whether the transporter proteins identified were functional, the ability of P-gp 
to transport Rh123 across the monolayer was measured.36 Papp from the lower to upper 
reservoir (Papp, B to U) was 7× greater than that from the upper to lower reservoir 
(Papp, U to B) confirming that Rh123 was preferentially transported into the upper or luminal 
compartment as described previously (Figure 4B).36 A Papp, B to U/ Papp, U to B exceeding 2 is 
characteristic of efflux secretory transport.37 The Papp, B to U/ Papp, U to B value of 7 is 
however lower than that typically reported in the literature for Caco-2 tumor cells 
(Papp, B to U/ Papp, U to B >10).36 Verapamil, another substrate for P-gp, should act as a 
competitive inhibitor of Rh123 when co- added with Rh123 providing confirmation that the 
observed movement of Rh123 is due to P-gp activity rather than another transporter.38 In the 
presence of verapamil, Papp for Rh123 decreased significantly (Figure 4B, p<0.001). These 
data support that active P-gp is present in these primary colonic monolayers, and the 
monolayers may serve as a platform for the investigation of drug-drug interactions involving 
P-gp.
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Measurement of SLC52A transporter activity in the monolayers.
Riboflavin (vitamin B2) is an important cofactor for redox intermediate flavin coenzymes 
(e.g. FAD and FAM) which play a key role in the metabolism of carbohydrates, amino acids 
and lipids.39,40 SLC52A transports riboflavin from the gut lumen across the epithelium and 
mutations in the SLC52A can lead to riboflavin deficiency.39,40 The mRNA expression data 
suggested that SLC transporters might be present in the colonic monolayers including 
SLC52A2 and SLC52A3. To demonstrate the absorption of important dietary compounds 
through the colonic monolayers, riboflavin transport was assayed by adding riboflavin (1 or 
5 μM) to the upper reservoir, but not the lower reservoir. The fractional absorption of 
riboflavin was measured over time (Figure 4C). The fractional riboflavin accumulation was 
significantly higher when the concentration was 1 μM compared to 5 μM at both 3 h and 24 
h. The riboflavin transporter is known to saturate at high riboflavin concentrations.41,42 
These data demonstrate active transport of a variety of molecules across the primary colonic 
monolayers enabling the tissues to serve as a platform for exploration and screening of 
dietary compound and drug absorption.
4 Conclusions
A gradient cross-linked collagen scaffold was developed to generate confluent monolayers 
of primary murine colonic epithelial cells. A gradient of amine-based crosslinking provided 
a scaffold surface that supported colonic cell adhesion, proliferation and generation of 
confluent monolayers with high TEER in a reproducible manner. The cross-linking strategy 
further solved the challenge of cell- mediated collagen contraction. The planar geometry of 
the platform produced in this work enabled ready access to both upper (luminal) and lower 
(basal) surfaces, a distinct advantage over organoid systems. Global mRNA expression 
profiles of colonic monolayers showed gene expression of monolayers by day 5 that highly 
correlated with native crypt tissue with differentiated and functional enterocytes. The 
monolayers possessed excellent integrity as evidenced by their high TEER and 
impermeability to LY. Many of the ABC and SLC family transporters in crypts were also 
expressed in day 5 monolayers and the monolayers were successfully used to demonstrate 
drug and nutrient transport and absorption using para- and passive transcellular, P-gp and 
solute carrier-based transporter specific substrates. The low Papp value of paracellular 
transport measurements indicated tight cellular contacts in our model. Further, P-gp-
mediated transport demonstrated that the monolayers extruded compounds, an important 
demonstration for future drug inhibition or drug-drug interaction assays. Riboflavin 
absorption through the riboflavin transporter provided evidence of colonic nutrient 
absorption utilizing SLC-based transporters. These features enable the colonic monolayers 
to be employed for drug transport, toxicity and screening assays.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Evaluation of collagen hydrogel scaffolds used for cell culture. Widefield Hoechst 33342 
(blue) and brightfield-merged images of cells on A) non cross-linked collagen and B) 
collagen with a gradient of cross-linking. Delamination of the collagen layer is seen in the 
upper and lower left quadrants in “A”. Scale bar = 2 mm. C) Schematic of the gradient 
cross-linking process. D & E) Electron microscopic images of the surface of non cross-
linked collagen (D) and collagen with a gradient of cross-linking (E). Scale bar = 1 μm. F) A 
comparison of colonic epithelial cell growth (2 days) on non cross-linked collagen and 
collagen with a gradient of cross-linking.
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Characterization of a colonic monolayers. A) Widefield and magnified images of a 
monolayer stained for F-actin (green) & nuclei (blue). The scale bar is 2 mm and 10 μm for 
widefield and magnified images respectively. B) Cross-sectioned monolayer stained for F-
actin (green), integrin β4 (red) and nuclei (blue). The scale bar is 10 μm. C & D) Staining of 
adherens junction protein, E-cadherin (red in C) and tight junction protein, ZO-1 (red in D) 
and nuclei, Hoechst 33342 (blue). The scale bar for C & D is 20 μm. E) Quantification of 
stained area for the different lineage markers over time as a percentage of the total Hoechst 
33342-positive area.
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Characterization of confluent monolayer integrity. A) Comparison of mRNA expression 
levels of tight and adherens junction genes over time. Statistical significance (Padj) between 
crypts and day 5 is shown with symbols as they were defined in methods. B) Experimental 
set up of LY permeability assay. C) Comparison of LY diffusion through colonic monolayers 
and a cellular cross-linked collagen scaffolds. D) LY permeability of the monolayer with 
respect to TEER.
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Compound transport across the monolayer: A) Permeability of the monolayers to ATL and 
PPL. B) P-gp-based efflux secretory transport and inhibition. Rh123 (10 µM) translocation 
through P-gp transporter and inhibition by verapamil (200 µM). C) A comparison of fraction 
of absorption of riboflavin (1 µM and 5 µM) at 3 h and 25 h.
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Table 1.
A comparison of mRNA and protein expression level of a selected set of transporters.
Transporter Protein expression level in 
monolayer
Protein expression level in 
crypts
mRNA expression level in 
monolayer
mRNA expression level in 
crypts
P-gp/Abcb1a +++ +++++ +++ +++
BCRP/Abcg2 + + ++ ++
MRP1/Abcc1 + + +++ ++
MRP3/Abcc3 + ++ +++ +++
NaK
ATPase/Atp1a1
++++ ++++++ ++++ ++++
mRNA data was measured at day 5 of culture while protein was measured at day 6 of culture. Protein comparison levels in pmol/mg membrane 
fraction protein (PL) are PL>50 (++++++); 17.5>PL>15 (+++++); 15>PL>12.5 (++++); 5>PL>2.5 (++); 2.5>PL>0.1 (+). mRNA expression 
comparison levels in counts per million (mRL) are 3<mRL<4 (++++); 2<mRL<3 (+++); 1<mRL<2 (++); 0.5<mRL<1 (+).
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